CMA
TXMD icon

Cedar Mountain Advisors’s TherapeuticsMD TXMD Stock Holding History

Cedar Mountain Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-40
Closed -$165 – 325
2023
Q2 		$165 Hold
40
– – ﹤0.01% 286
2023
Q1 		$150 Buy
+40
New +$192 ﹤0.01% 284

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cedar Mountain Advisors's TXMD Position: Q3 2023 in Review

Cedar Mountain Advisors sold out of TherapeuticsMD (TXMD) in Q3 2023, closing a stake of 40 shares — an estimated $165 sold.

Cedar Mountain Advisors first reported a position in TXMD in Q1 2023 and held it in 2 quarters. The position peaked at $165 in Q2 2023. 36 funds tracked by Wall St. Rank hold TXMD as of Q3 2023.

  • Cedar Mountain Advisors reported no remaining TherapeuticsMD position as of Q3 2023 after selling out during the quarter.
  • Cedar Mountain Advisors sold 40 TherapeuticsMD shares in Q3 2023, an estimated $165.
  • Cedar Mountain Advisors first reported a position in TherapeuticsMD in Q1 2023 and held it in 2 quarters.
  • Cedar Mountain Advisors's TherapeuticsMD position peaked at $165 in Q2 2023.
  • 36 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2023.

Based on Cedar Mountain Advisors's 13F filing for Q3 2023, filed 23 Oct 2023.